share_log

Cantor Fitzgerald Reiterates Neutral on Verve Therapeutics, Maintains $22 Price Target

Benzinga ·  Sep 13, 2023 08:49

Cantor Fitzgerald analyst Rick Bienkowski reiterates Verve Therapeutics (NASDAQ:VERV) with a Neutral and maintains $22 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment